TB-500

Thymosin beta-4 is a naturally occurring protein of 43 amino acids and one of the most abundant actin-sequestering molecules in mammalian cells. TB-500 is not that protein. It is a research-supply designation for a much shorter synthetic peptide corresponding to the actin-binding region, most often the LKKTETQ motif.

This distinction is the single most important fact for a purchasing laboratory, because supplier listings routinely blur it. A vial labelled TB-500 and a vial labelled thymosin beta-4 are different materials with different molecular weights, different chromatographic behaviour and different literature. Verify the sequence stated on the certificate rather than inferring it from the product name.

The practical consequence is that published results attributed to thymosin beta-4 cannot be assumed to transfer to a short fragment, and vice versa. Any experimental design that cites the parent protein's literature while using a fragment should state that substitution explicitly.

Thymosin beta-4 was characterised in the 1980s and has a substantial literature covering actin sequestration, cell migration, angiogenesis markers and corneal and dermal repair models. Work on the isolated actin-binding fragment is narrower and more recent, and much of it examines whether the short motif reproduces the behaviour of the full protein in a given assay.

As with other repair-associated peptides, the evidence base is preclinical: cell monolayers, migration and scratch assays, and animal injury models. No regulator has approved TB-500 as a medicine, and VaultLabs makes no claim about human effects.

Thymosin beta-4 and related peptides are prohibited in sport under the World Anti-Doping Agency list. Laboratories connected to athlete populations or testing programmes should treat storage and accountability of this material accordingly.

Release is by reversed-phase HPLC against a stated purity specification, with the certificate tied to the vial lot number. Short peptide fragments are particularly worth confirming by mass where the capability exists, because sequence errors and truncations are not always resolved chromatographically.

Fragment peptides are sensitive to oxidation and to proteolysis once a vial has been opened and contamination introduced. Minimise open-vial time, work aseptically, and record handling steps. Store sealed lyophilised material at 2–8 °C protected from light, and move deliveries into cold storage promptly on arrival.

After reconstitution, prepare working solutions close to the point of use and keep freeze-thaw cycles low and logged. The certified purity applies to the lyophilised material as released, not to a solution that has been stored and cycled.

TB-500 is supplied as a research reference material. It is not a registered medicine in the United Arab Emirates and is not supplied for human or veterinary use. The research-use declaration recorded at checkout forms part of the order documentation.

TB-500 is also a named component of the KLOW multi-peptide blend. Where a laboratory is evaluating the blend, each constituent should be assessed against its own documentation rather than a single composite figure.

Cell migration assays

Actin cytoskeleton studies

Cardiac and dermal fibroblast models

Wound closure kinetics (in vitro)

2–8 °C (lyophilized, sealed)

Lyophilized material: 2–8 °C sealed. Protect from light. Gulf climate logistics may require expedited transfer to laboratory cold storage on receipt.

Peptide fragments are sensitive to oxidation and proteolysis after reconstitution. Minimize open-vial time and document handling steps.